LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $34.00 thousand for the 7-month period ending 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-05-25 was $0.00.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-02-23 was $0.00.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-11-24 was $0.00.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-08-25 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $115.00K.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $300.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $34.00K 10-KT · filed 2026-03-16 | |||||
| 2025-05-25 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 10-KT · filed 2026-03-16 | ||
| 2025-02-23 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-03 | $0.00 derived: sum of 2 quarters · filed 2025-04-03 | $0.00 10-Q · filed 2025-04-03 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-11-24 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | $0.00 10-Q · filed 2025-01-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-08-25 | $0.00 10-Q · filed 2024-10-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $0.00 derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-05-26 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $115.00K 10-KT · filed 2026-03-16 | ||
| 2024-02-25 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-03 | $0.00 derived: sum of 2 quarters · filed 2025-04-03 | $115.00K 10-Q · filed 2025-04-03 | |||
| 2023-11-26 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $115.00K 10-Q · filed 2024-08-09 | ||||
| 2023-08-27 | $115.00K 10-Q · filed 2024-08-09 | |||||
| 2023-05-28 | $0.00 10-K · filed 2024-08-26 | $12.07K 10-K · filed 2024-03-20 | ||||
| 2022-05-29 | $300.00K 10-K · filed 2024-08-26 | $304.21K 10-K · filed 2022-09-14 | ||||
| 2021-05-30 | $0.00 10-K/A · filed 2023-03-16 | |||||
| 2020-05-31 | $169.07K 10-K/A · filed 2023-03-16 | |||||
| 2019-05-26 | $265.91K 10-K · filed 2021-07-29 | |||||
| 2018-05-27 | $177.92K 10-K · filed 2020-08-14 | $178.00K 10-K · filed 2018-08-09 | ||||
| 2017-05-28 | $2.80M 10-K/A · filed 2018-03-15 | |||||
| 2016-05-29 | $1.10M 10-K · filed 2016-08-01 | |||||
| 2015-05-31 | $1.50M 10-K · filed 2015-07-31 | |||||
| 2014-05-25 | $2.30M 10-K · filed 2014-08-01 | |||||
| 2013-05-26 | $4.10M 10-K · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |